EQRx, Inc.
EQRx, Inc. (EQRX): 5 pipeline candidates · ~57 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
56.9 months
D/E 0.06 · 0% dilution
Lead: Phase 3
5 candidates
N/A
N/A
A transparent, data-derived signal for EQRx, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$316.3M
Quarterly Burn
$61.9M
Runway
56.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| aumolertinib | Phase 3 |
| eq121 | Phase 2 |
| lerociclib | Phase 2 |
| nofazinlimab | Phase 3 |
| sugemalimab | Phase 3 |
Frequently asked questions
How many drug candidates are in EQRx, Inc.'s pipeline?
EQRx, Inc. (EQRX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is EQRx, Inc.'s lead drug candidate?
EQRx, Inc.'s most advanced tracked candidate is aumolertinib (Phase 3) for EGFR-mutated non-small cell lung cancer (NSCLC).
What is EQRx, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, EQRx, Inc. has approximately 56.9 months of cash runway.
Who is the CEO of EQRx, Inc.?
Massachusetts August is the chief executive officer of EQRx, Inc. (EQRX).
Get the full picture on EQRx, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.